Life Sciences

Aug 285 min read

The eight factors that will determine the impact of GLP-1s

In last week's blog post, we delved into the what and why behind the current surge in interest and demand for GLP-1s. And it's clear that...

Aug 216 min read

The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024

A full 6% of US adults are taking GLP-1s. In this post, we break down what we do—and don't—know about these medications as of August 2024.

Jun 75 min read

Theory versus reality in the state of healthcare disruption

Healthcare disruption has been a hot (and noisy) topic in recent years. For the last decade, the healthcare industry has been rich in...

Mar 263 min read

The wheel turns on the PBMs

Everybody likes to pick on the PBMs (pharmacy benefit managers) these days. It's a sector of healthcare whose business model...

Feb 11 min read

Breakthrough drugs to strain price and volume

Something we're starting new this week: Union Healthcare Insight's Slide of the Week. Over the past 12 months we've been in business, our...

Oct 5, 20233 min read

Drug shortages for the uninitiated

This month, my family and I were affected by two different drug shortages. First, we couldn’t fill a standing prescription for an ADHD...

Sep 6, 20238 min read

The real impact of the IRA drug price controls

Cost savings for seniors are real—but there are thousands of ways to squeeze the balloon When the Inflation Reduction Act passed in 2022,...

Join our mailing list

Get access to our latest posts